MX2021008999A - Agentes radiotrazadores y agentes terapeuticos de modo doble, que se unen al antigeno de membrana especifico de la prostata. - Google Patents
Agentes radiotrazadores y agentes terapeuticos de modo doble, que se unen al antigeno de membrana especifico de la prostata.Info
- Publication number
- MX2021008999A MX2021008999A MX2021008999A MX2021008999A MX2021008999A MX 2021008999 A MX2021008999 A MX 2021008999A MX 2021008999 A MX2021008999 A MX 2021008999A MX 2021008999 A MX2021008999 A MX 2021008999A MX 2021008999 A MX2021008999 A MX 2021008999A
- Authority
- MX
- Mexico
- Prior art keywords
- radiotracer
- therapeutic
- dual mode
- psma binding
- binding dual
- Prior art date
Links
- 230000009977 dual effect Effects 0.000 title 1
- 239000000700 radioactive tracer Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Circuits Of Receivers In General (AREA)
- Compounds Of Unknown Constitution (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nuclear Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Toys (AREA)
- Electrotherapy Devices (AREA)
Abstract
La presente invención se refiere a un compuesto según la fórmula (V): (ver Fórmula) o a una sal farmacéuticamente aceptable del mismo, que contiene opcionalmente un catión radiactivo quelado y en donde F es opcionalmente 18F.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19154500 | 2019-01-30 | ||
| PCT/EP2020/052248 WO2020157177A1 (en) | 2019-01-30 | 2020-01-30 | Psma binding dual mode radiotracer and therapeutic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008999A true MX2021008999A (es) | 2021-11-04 |
Family
ID=65268810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008999A MX2021008999A (es) | 2019-01-30 | 2020-01-30 | Agentes radiotrazadores y agentes terapeuticos de modo doble, que se unen al antigeno de membrana especifico de la prostata. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220096668A1 (es) |
| EP (2) | EP4249456A3 (es) |
| JP (2) | JP2022523727A (es) |
| KR (1) | KR20210153037A (es) |
| CN (2) | CN116675730A (es) |
| AU (2) | AU2020213678B2 (es) |
| BR (1) | BR112021014933A2 (es) |
| CA (1) | CA3128401A1 (es) |
| DK (1) | DK3917626T3 (es) |
| EA (1) | EA202191691A1 (es) |
| ES (1) | ES2953196T3 (es) |
| FI (1) | FI3917626T3 (es) |
| HU (1) | HUE063038T2 (es) |
| IL (2) | IL303421A (es) |
| MX (1) | MX2021008999A (es) |
| PL (1) | PL3917626T3 (es) |
| PT (1) | PT3917626T (es) |
| SG (1) | SG11202108109RA (es) |
| WO (1) | WO2020157177A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230277698A1 (en) * | 2020-07-23 | 2023-09-07 | Technische Universität München | Silicon-containing ligand compounds |
| EP4023250A1 (en) * | 2021-01-04 | 2022-07-06 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| CN117120099A (zh) * | 2021-02-15 | 2023-11-24 | 慕尼黑工业大学 | 双模式放射性示踪剂和疗法 |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| GB202113646D0 (en) | 2021-09-24 | 2021-11-10 | Blue Earth Diagnostics Ltd | Method of preparation of 18F labelled silyl-fluoride compounds |
| CA3232149A1 (en) * | 2021-09-28 | 2023-04-06 | Antelope Surgical Solutions, Inc. | Multifunctional compounds for use in medical imaging and therapy |
| GB202207372D0 (en) | 2022-05-19 | 2022-07-06 | Blue Earth Diagnostics Ltd | Synthesis of fluorosilyl compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2097111T1 (sl) * | 2006-11-08 | 2016-02-29 | Molecular Insight Pharmaceuticals, Inc. | Heterodimeri glutaminske kisline |
| WO2012087912A1 (en) * | 2010-12-22 | 2012-06-28 | Ge Healthcare Limited | Her2 binding peptides labelled with a 18f - containing organosilicon compound |
| CN102626522B (zh) * | 2012-04-12 | 2014-09-10 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
| KR20200064057A (ko) * | 2017-07-28 | 2020-06-05 | 테크니쉐 우니베르지테트 뮌헨 | 이중 모드 방사성 트레이서 및 치료법 |
-
2020
- 2020-01-30 US US17/426,962 patent/US20220096668A1/en active Pending
- 2020-01-30 EA EA202191691A patent/EA202191691A1/ru unknown
- 2020-01-30 HU HUE20702636A patent/HUE063038T2/hu unknown
- 2020-01-30 WO PCT/EP2020/052248 patent/WO2020157177A1/en unknown
- 2020-01-30 IL IL303421A patent/IL303421A/en unknown
- 2020-01-30 MX MX2021008999A patent/MX2021008999A/es unknown
- 2020-01-30 CN CN202310616797.7A patent/CN116675730A/zh active Pending
- 2020-01-30 ES ES20702636T patent/ES2953196T3/es active Active
- 2020-01-30 BR BR112021014933-3A patent/BR112021014933A2/pt unknown
- 2020-01-30 PT PT207026360T patent/PT3917626T/pt unknown
- 2020-01-30 KR KR1020217027178A patent/KR20210153037A/ko unknown
- 2020-01-30 SG SG11202108109RA patent/SG11202108109RA/en unknown
- 2020-01-30 CA CA3128401A patent/CA3128401A1/en active Pending
- 2020-01-30 JP JP2021544525A patent/JP2022523727A/ja active Pending
- 2020-01-30 EP EP23167668.5A patent/EP4249456A3/en active Pending
- 2020-01-30 CN CN202080024836.9A patent/CN113677400B/zh active Active
- 2020-01-30 DK DK20702636.0T patent/DK3917626T3/da active
- 2020-01-30 FI FIEP20702636.0T patent/FI3917626T3/fi active
- 2020-01-30 PL PL20702636.0T patent/PL3917626T3/pl unknown
- 2020-01-30 AU AU2020213678A patent/AU2020213678B2/en active Active
- 2020-01-30 EP EP20702636.0A patent/EP3917626B1/en active Active
-
2021
- 2021-07-19 IL IL284958A patent/IL284958A/en unknown
-
2023
- 2023-06-05 AU AU2023203501A patent/AU2023203501A1/en active Pending
-
2024
- 2024-03-22 JP JP2024046097A patent/JP2024073651A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL284958A (en) | 2021-09-30 |
| EP4249456A2 (en) | 2023-09-27 |
| AU2023203501A1 (en) | 2023-07-06 |
| PT3917626T (pt) | 2023-08-23 |
| WO2020157177A1 (en) | 2020-08-06 |
| CN113677400A (zh) | 2021-11-19 |
| IL303421A (en) | 2023-08-01 |
| JP2024073651A (ja) | 2024-05-29 |
| BR112021014933A2 (pt) | 2021-10-05 |
| AU2020213678A1 (en) | 2021-08-12 |
| AU2020213678B2 (en) | 2024-05-30 |
| US20220096668A1 (en) | 2022-03-31 |
| CA3128401A1 (en) | 2020-08-06 |
| HUE063038T2 (hu) | 2023-12-28 |
| PL3917626T3 (pl) | 2023-11-27 |
| EP4249456A3 (en) | 2023-10-11 |
| JP2022523727A (ja) | 2022-04-26 |
| SG11202108109RA (en) | 2021-08-30 |
| KR20210153037A (ko) | 2021-12-16 |
| EP3917626B1 (en) | 2023-05-31 |
| DK3917626T3 (da) | 2023-08-28 |
| FI3917626T3 (fi) | 2023-08-17 |
| CN116675730A (zh) | 2023-09-01 |
| EA202191691A1 (ru) | 2021-11-01 |
| EP3917626A1 (en) | 2021-12-08 |
| CN113677400B (zh) | 2023-12-01 |
| ES2953196T3 (es) | 2023-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021008999A (es) | Agentes radiotrazadores y agentes terapeuticos de modo doble, que se unen al antigeno de membrana especifico de la prostata. | |
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| TW200728307A (en) | Novel spirochromanone derivatives | |
| CR20210032A (es) | Compuestos | |
| EA033168B1 (ru) | СТИМУЛЯТОРЫ sGC | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| IL157254A0 (en) | N-substituted nonaryl-heterocyclic nmda/mr2b antagonists | |
| MXPA02003977A (es) | Inhibidores de adhesion de celula mediada por al°2. | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| MX2022006470A (es) | Tiromimeticos novedosos. | |
| MY139704A (en) | Naphthalene derivatives for use as histamine-3-receptor ligands | |
| MX2021013055A (es) | Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos. | |
| MX2020002430A (es) | Compuestos inhibidores del receptor 1 del acido lisofosfatidico (lpar1). | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| MX2021012105A (es) | Compuestos de pirrol. | |
| SG10201806809QA (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| MX2020008498A (es) | Derivados de sobetirome. | |
| MX2021014680A (es) | Derivado de benzotriazol. | |
| MX2022003504A (es) | Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo. | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| PH12020551341A1 (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
| SG11201907945YA (en) | Azetidine derivative | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| EP1617806A4 (en) | SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MODULATORS | |
| MX2022004215A (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4. |